Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Connect Biopharma is a clinical-stage biopharmaceutical company developing monoclonal antibodies targeting respiratory diseases like asthma and COPD. Its lead product, rademikibart, inhibits IL-4Rα to treat eosinophilic inflammation, aiming to improve acute and chronic care. The company focuses on innovative therapies, clinical trials, and strategic collaborations, with a pipeline addressing significant unmet medical needs in respiratory and inflammatory conditions.
This description was generated via AI from an annual report. Updated about 1 year ago.